Details for New Drug Application (NDA): 219847
✉ Email this page to a colleague
NDA 219847 describes ARYNTA, which is a drug marketed by Azurity and is included in one NDA. There are two patents protecting this drug. Additional details are available on the ARYNTA profile page.
The generic ingredient in ARYNTA is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
The generic ingredient in ARYNTA is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for 219847
| Tradename: | ARYNTA |
| Applicant: | Azurity |
| Ingredient: | lisdexamfetamine dimesylate |
| Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 219847
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 10MG/ML | ||||
| Approval Date: | Jun 16, 2025 | TE: | RLD: | Yes | |||||
| Patent: | 11,576,878 | Patent Expiration: | Aug 30, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 12,433,859 | Patent Expiration: | Apr 16, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | ||||||||
Complete Access Available with Subscription
